---
layout: post
title: "Stimulant Use Disorders: Developing Drugs for Treatment; Draft Guidance for Industry; Availability"
date: 2026-02-05 18:57:08 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2023-22189
original_published: 2023-10-05 00:00:00 +0000
significance: 8.00
---

# Stimulant Use Disorders: Developing Drugs for Treatment; Draft Guidance for Industry; Availability

**Published:** February 05, 2026 18:57 UTC
**Source:** Federal Register
**Original Published:** October 05, 2023 00:00 UTC
**Document Number:** 2023-22189

## Summary

The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry entitled "Stimulant Use Disorders: Developing Drugs for Treatment." The purpose of this draft guidance is to assist sponsors in the clinical development of drugs for the treatment of stimulant use disorders. Specifically, this guidance addresses FDA's current recommendations regarding the overall development program and clinical trial designs for the development of drugs to support indications of treatment of moderate to severe cocaine use disorder, treatment of moderate to severe methamphetamine use disorder, or treatment of moderate to severe prescription stimulant use disorder.

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2023/10/05/2023-22189/stimulant-use-disorders-developing-drugs-for-treatment-draft-guidance-for-industry-availability)
- API: https://www.federalregister.gov/api/v1/documents/2023-22189

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
